Clinical Trials Logo
  1. Home
  2. Cardiogenic Shock
  3. NCT05728359

Genomic Determinants of Outcome in Cardiogenic Shock — Goldilocs  

Cardiogenic Shock Clinical Trial

Official title:
Prospective Observational Study Investigating Genomic Determinants of Outcome From Cardiogenic Shock (GOlDilOCS)

Clinical Trial Summary

The aim of this project is to understand the heterogeneity of both the immune consequences and treatment responses in CS. We will explore this heterogeneity through identification of transcriptomic sub-phenotypes and their association with outcomes, including therapeutic responses.

Clinical Trial Description

This is a prospective observational cohort study in 8-10 cardiac centres across Europe. We will recruit patients presenting with acute myocardial infarction (AMI) and CS who are supported medically (n=100); with extracorporeal membrane oxygenation (n=50); and with the Impella Device (n=50). We will also enrol patients who present with either AMI and no evidence of CS (n=50) or CS due to non-ischaemic pathologies (e.g. myocarditis: n=50) as comparators. The recruitment target is 300 patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05728359
Study type Observational [Patient Registry]
Source Barts & The London NHS Trust
Contact Alastair Proudfoot
Phone 02037658707
Email alastair.proudfoot1@nhs.net
Status Recruiting
Phase
Start date September 20, 2022
Completion date July 1, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03283995 - Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
Active, not recruiting NCT04325035 - The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock Phase 2
Active, not recruiting NCT05100836 - SURPASS Impella 5.5 Study
Not yet recruiting NCT05106491 - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients N/A
Completed NCT02301819 - ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock N/A
Completed NCT01367743 - Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock Phase 4
Recruiting NCT05699005 - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Phase 1
Not yet recruiting NCT06338345 - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients N/A
Completed NCT03436641 - Microcirculation in Cardiogenic Shock
Recruiting NCT03313687 - SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
Recruiting NCT05506449 - The RECOVER IV Trial N/A
Completed NCT04144660 - "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Completed NCT04548739 - Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Recruiting NCT04141410 - Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
Not yet recruiting NCT05879276 - Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. Phase 3
Enrolling by invitation NCT05570864 - Score TO Predict SHOCK - STOP SHOCK
Completed NCT02591771 - Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock Phase 2
Terminated NCT02279979 - Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial N/A
Completed NCT01374867 - CardShock Study and Registry N/A
Recruiting NCT00093301 - Levosimendan Versus Dobutamine in Shock Patients Phase 2/Phase 3